LIVE WEBINAR
Thursday, September 28 | 11am ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording. ​

Generative artificial intelligence (AI) dominates the headlines today. Some predict that AI will unleash unprecedented productivity, efficiency and wealth, while others worry that AI will take away jobs, manipulate elections and concentrate wealth and power. 

Most of these discussions are hypothetical, but in life sciences, AI’s potential to revolutionize one critically important task is abundantly clear: it promises to significantly accelerate the regulatory approval process. In this webinar our team of experts explain how AI is already changing the game in the regulatory approval process, including:

• The connection between existing manual approaches to regulatory approvals and the typical 10+ year drug development timeline
• Why relatively few pharmaceutical companies have been willing to embrace new technologies like AI
• Specific use cases and scenarios where AI can (and cannot) be integrated into the approval process

SPEAKERS

Andrew Robertson, PhD, JD
Vice President, Global Regulatory Policy and Innovation
Takeda

Lyn Hopkinson
Regulatory Affairs and Quality Executive
CoRA Consulting LLC

Lisa MacNeir
Executive Director of Global Labeling and Regulatory Operations
Stemline